Tissue polypeptide antigen (TPA) in pleural effusions.
The usefulness of tumor marker assay in pleural effusions for differential diagnosis is still debated. From the observation of common antigens on tissue polypeptide antigen (TPA) and keratins 8, 18 and 19 and vimentin, all substances contained in normal and neoplastic mesothelium, we felt it opportune to evaluate the use of TPA assay in 105 pleural effusions (46 benign and 59 malignant). The values were much higher than those found in blood. In hydrothorax the median value was 454 U/l (range, 59-1923), in exudative effusions 846 U/l (range, 258-4485), in metastatic pleural effusions 1277 U/l (range, 58-32352) and in mesotheliomas 7705 (range, 759-16000). The maximum value found in nonmalignant effusions was 4485 U/l; this value was taken as a cutoff level, so only 29.9% of the tumors were positive to the test. Our results showed this assay to be not very important for a differential diagnosis of malignant and nonmalignant pleural effusions. Nevertheless, the different TPA patterns in mesotheliomas (66.6% positive) and metastatic pleural effusions (15.9%) suggest that further studies are warranted.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007633:Keratins / Q000032:analysis* / Q000276:immunology; D008297:Male; D008654:Mesothelioma / Q000175:diagnosis* / Q000276:immunology; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis* / Q000276:immunology; D010455:Peptides / Q000032:analysis*; D010995:Pleural Diseases / Q000175:diagnosis*; D010996:Pleural Effusion / Q000276:immunology*; D010997:Pleural Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000556:secondary; D019396:Tissue Polypeptide Antigen; D014746:Vimentin / Q000032:analysis* / Q000276:immunology
D000951:Antigens, Neoplasm; D009363:Neoplasm Proteins; D010455:Peptides; D019396:Tissue Polypeptide Antigen; D014746:Vimentin; D007633:Keratins